BR0209269A - Terapia de combinação antiangiogênica para o tratamento de câncer - Google Patents
Terapia de combinação antiangiogênica para o tratamento de câncerInfo
- Publication number
- BR0209269A BR0209269A BR0209269-7A BR0209269A BR0209269A BR 0209269 A BR0209269 A BR 0209269A BR 0209269 A BR0209269 A BR 0209269A BR 0209269 A BR0209269 A BR 0209269A
- Authority
- BR
- Brazil
- Prior art keywords
- combination therapy
- cancer treatment
- antiangiogenic
- antiangiogenic combination
- inhibitory agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"TERAPIA DE COMBINAçãO ANTIANGIOGêNICA PARA O TRATAMENTO DE CâNCER". A presente invenção proporciona combinações de um agente inibidor de topoisomerase I de DNA e de um agente inibidor seletivo COX-2 para prevenir, tratar e/ou reduzir o risco de desenvolver um distúrbio neoplásico em um mamífero.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/843,132 US20020103141A1 (en) | 1998-12-23 | 2001-04-25 | Antiangiogenic combination therapy for the treatment of cancer |
PCT/US2002/013219 WO2002085459A2 (en) | 2001-04-25 | 2002-04-25 | Antiangiogenic combination therapy for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0209269A true BR0209269A (pt) | 2004-06-22 |
Family
ID=25289143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0209269-7A BR0209269A (pt) | 2001-04-25 | 2002-04-25 | Terapia de combinação antiangiogênica para o tratamento de câncer |
Country Status (15)
Country | Link |
---|---|
US (2) | US20020103141A1 (pt) |
EP (1) | EP1414526A2 (pt) |
JP (1) | JP2004529150A (pt) |
KR (1) | KR20040018364A (pt) |
CN (1) | CN1520324A (pt) |
BR (1) | BR0209269A (pt) |
CA (1) | CA2444219A1 (pt) |
CZ (1) | CZ20032783A3 (pt) |
EA (1) | EA200301104A1 (pt) |
IL (1) | IL158329A0 (pt) |
MX (1) | MXPA03009886A (pt) |
NO (1) | NO20034780L (pt) |
PL (1) | PL367198A1 (pt) |
WO (1) | WO2002085459A2 (pt) |
ZA (1) | ZA200402546B (pt) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040127470A1 (en) * | 1998-12-23 | 2004-07-01 | Pharmacia Corporation | Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist |
WO2003030864A1 (en) * | 2001-05-29 | 2003-04-17 | Neopharm, Inc. | Liposomal formulation of irinotecan |
CA2383259A1 (en) * | 2002-04-23 | 2003-10-23 | Celator Technologies Inc. | Synergistic compositions |
EP1318405B1 (de) * | 2001-12-04 | 2004-11-17 | B.R.A.H.M.S Aktiengesellschaft | Verfahren zur Diagnose von Sepsis unter Bestimmung löslicher Cytokeratinfragmente |
GB0208516D0 (en) * | 2002-04-15 | 2002-05-22 | Univ Liverpool | Chemotherapy |
AU2003296897A1 (en) * | 2002-08-20 | 2004-05-04 | Neopharm, Inc. | Pharmaceutical formulations of camptothecine derivatives |
US20060030578A1 (en) * | 2002-08-20 | 2006-02-09 | Neopharm, Inc. | Pharmaceutically active lipid based formulation of irinotecan |
US20040152632A1 (en) * | 2002-11-06 | 2004-08-05 | Wyeth | Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome |
MXPA05004711A (es) * | 2002-11-06 | 2005-08-03 | Wyeth Corp | Terapia combinada para el tratamiento de leucemia aguda y sindrome mielodisplasico. |
US7332525B2 (en) | 2003-01-17 | 2008-02-19 | Castle Erik P | Method of treatment of prostate cancer and composition for treatment thereof |
US20050187172A1 (en) * | 2003-12-23 | 2005-08-25 | Masferrer Jaime L. | Combination of a Cox-2 inhibitor and a DNA topoisomerase I inhibitor for treatment of neoplasia |
CA2574363A1 (en) * | 2004-07-23 | 2006-02-02 | Pharmacia & Upjohn Company Llc | Enantioselective method for separating sustituted 2-trifluoromethyl-2h-chromene-3-carboxylic acid derivatives |
US7122700B2 (en) | 2004-07-30 | 2006-10-17 | Xerox Corporation | Arylamine processes |
CA2589521C (en) * | 2004-12-15 | 2014-04-01 | Novartis Ag | Combinations of 7-t-butoxyiminomethylcamptothecin with one or more chemotherapeutic agents for treating cancers |
WO2008020032A1 (en) * | 2006-08-16 | 2008-02-21 | Action Medicines, S.L. | Use of 2,5-dihydroxybenzene derivatives for the treatment of ocular diseases |
CN101971027A (zh) | 2008-01-23 | 2011-02-09 | 海莱乌医院 | 作为非特异疾病的通用标记的ykl-40 |
EP2338486A1 (en) | 2009-12-18 | 2011-06-29 | Johannes Gutenberg-Universität Mainz | 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma |
GB201000196D0 (en) * | 2010-01-07 | 2010-02-24 | Galvez Julian M | Novel combination |
US9125899B1 (en) | 2010-06-17 | 2015-09-08 | Stc.Unm | Modulators of GTPases and their use |
ES2731725T3 (es) * | 2012-11-28 | 2019-11-18 | Nektar Therapeutics | Método para evaluar y predecir la eficacia del tratamiento del cáncer de mama con un inhibidor de la topoisomerasa I de acción prolongada |
CN103012350B (zh) * | 2012-12-07 | 2015-02-04 | 中国科学院广州生物医药与健康研究院 | 苯并吡喃类手性化合物的合成方法 |
TWI646091B (zh) | 2012-12-28 | 2019-01-01 | 日商衛斯克慧特股份有限公司 | 鹽類及晶形 |
CN110997008A (zh) | 2017-06-12 | 2020-04-10 | 斯坦尼斯劳·R·布任斯基 | 用于治疗软脑膜疾病的方法 |
US11344521B2 (en) | 2017-06-12 | 2022-05-31 | Burzynski Research Institute, Inc. | Methods for the treatment of leptomeningeal disease |
JP7268049B2 (ja) | 2018-03-08 | 2023-05-02 | インサイト・コーポレイション | PI3K-γ阻害剤としてのアミノピラジンジオール化合物 |
WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE399547T1 (de) * | 1996-10-15 | 2008-07-15 | Searle Llc | Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und vorbeugung von neoplasia |
US6034256A (en) * | 1997-04-21 | 2000-03-07 | G.D. Searle & Co. | Substituted benzopyran derivatives for the treatment of inflammation |
US6077850A (en) * | 1997-04-21 | 2000-06-20 | G.D. Searle & Co. | Substituted benzopyran analogs for the treatment of inflammation |
PA8469501A1 (es) * | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
PA8469401A1 (es) * | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
ES2220004T3 (es) * | 1998-04-10 | 2004-12-01 | Pfizer Products Inc. | Derivados del acido ciclobutil-ariloxiarilsulfonilaminohidroxamico. |
US6294558B1 (en) * | 1999-05-31 | 2001-09-25 | Pfizer Inc. | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents |
US6277878B1 (en) * | 1998-09-07 | 2001-08-21 | Pfizer Inc | Substituted indole compounds as anti-inflammatory and analgesic agents |
ES2213985T3 (es) * | 1998-11-05 | 2004-09-01 | Pfizer Products Inc. | Derivados de hidroxiamida de acido 5-oxo-pirrolidin-2-carboxilico. |
WO2000038786A2 (en) * | 1998-12-23 | 2000-07-06 | G.D. Searle & Co. | Use of cyclooxygenase 2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia |
ES2200783T3 (es) * | 1999-03-31 | 2004-03-16 | Pfizer Products Inc. | Acidos dioxociclopentil hidroxamicos. |
MXPA00006605A (es) * | 1999-07-02 | 2004-12-09 | Pfizer | Compuestos de carbonil-indol biciclicos como agentes antiinflamatorios/analgesicos. |
-
2001
- 2001-04-25 US US09/843,132 patent/US20020103141A1/en not_active Abandoned
-
2002
- 2002-04-25 IL IL15832902A patent/IL158329A0/xx unknown
- 2002-04-25 PL PL02367198A patent/PL367198A1/xx not_active Application Discontinuation
- 2002-04-25 MX MXPA03009886A patent/MXPA03009886A/es not_active Application Discontinuation
- 2002-04-25 EA EA200301104A patent/EA200301104A1/ru unknown
- 2002-04-25 WO PCT/US2002/013219 patent/WO2002085459A2/en active Application Filing
- 2002-04-25 EP EP02731524A patent/EP1414526A2/en not_active Withdrawn
- 2002-04-25 CN CNA028126319A patent/CN1520324A/zh active Pending
- 2002-04-25 CZ CZ20032783A patent/CZ20032783A3/cs unknown
- 2002-04-25 BR BR0209269-7A patent/BR0209269A/pt not_active IP Right Cessation
- 2002-04-25 CA CA002444219A patent/CA2444219A1/en not_active Abandoned
- 2002-04-25 KR KR10-2003-7014051A patent/KR20040018364A/ko not_active Application Discontinuation
- 2002-04-25 JP JP2002583032A patent/JP2004529150A/ja not_active Withdrawn
-
2003
- 2003-10-24 NO NO20034780A patent/NO20034780L/no not_active Application Discontinuation
- 2003-10-24 US US10/692,643 patent/US20040127539A1/en not_active Abandoned
-
2004
- 2004-03-31 ZA ZA200402546A patent/ZA200402546B/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20040018364A (ko) | 2004-03-03 |
PL367198A1 (en) | 2005-02-21 |
NO20034780D0 (no) | 2003-10-24 |
US20020103141A1 (en) | 2002-08-01 |
JP2004529150A (ja) | 2004-09-24 |
EP1414526A2 (en) | 2004-05-06 |
CN1520324A (zh) | 2004-08-11 |
US20040127539A1 (en) | 2004-07-01 |
ZA200402546B (en) | 2005-04-26 |
NO20034780L (no) | 2003-12-12 |
EA200301104A1 (ru) | 2004-06-24 |
WO2002085459A2 (en) | 2002-10-31 |
CZ20032783A3 (cs) | 2004-11-10 |
IL158329A0 (en) | 2004-05-12 |
MXPA03009886A (es) | 2004-11-22 |
CA2444219A1 (en) | 2002-10-31 |
WO2002085459A3 (en) | 2004-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0209269A (pt) | Terapia de combinação antiangiogênica para o tratamento de câncer | |
TR200102499T2 (tr) | Neoplazi tedavisinde bir kombinasyon terapisi olarak bir siklooksijenaz-2 inhibitörü ve bir veya daha fazla antineoplastik ajan kullanma yöntemi | |
BR9811946A (pt) | Método para prevenção ou tratamento de distúrbios e doenças dependentes de estrogênio | |
ATE430570T1 (de) | Synergistische kombinationstherapie zur krebsbehandlung | |
BR0211978A (pt) | Terapia de combinação para o tratamento de câncer | |
WO2004050026A3 (en) | Compositions and methods for treating prostate cancer | |
IL143805A0 (en) | Combination therapy of radiation and a cox-2 inhibitor for the treatment of neoplasia | |
HUP0303917A2 (hu) | Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére | |
BRPI0415896A (pt) | combinações compreendendo um inibidor de hsp90 e um inibidor de fosfodiesterase para tratamento ou prevenção de neoplasia | |
BRPI0408491A (pt) | tratamento da doença de alzheimer | |
BR9814419A (pt) | "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas" | |
MXPA03008582A (es) | Agentes y metodos para tratamiento de cancer. | |
BRPI0409473A (pt) | combinação de um inibidor de cox-2 e um agente antineoplásico do tipo alquilante para o tratamento de neoplasia | |
MX2022014180A (es) | Metodos, terapias y usos para tratar cancer. | |
BR0311146A (pt) | Uso de tibolona e de modulador de receptor de estrogênio seletivo, e, método e kit para o tratamento de um sintoma relacionado com a deficiência de estrogênio em um paciente do sexo feminino | |
IS2869B (is) | Notkun fúlvestrants við meðhöndlun á þrálátu brjóstakrabbameini | |
DK1133296T3 (da) | Ny terapeutisk anvendelse af nicergolin | |
BR0317491A (pt) | Método de usar um inibidor de cox-2 e um inibidor de topoisomerase ii como uma terapia de combinação no tratamento de neoplasia | |
BR0212446A (pt) | Uso de 4-piridilmetilftalazinas para tratamento de câncer | |
WO2003079748A3 (en) | Potentiation of cancer therapies by znf217 inhibition | |
BR0308976A (pt) | Terapia combinada contra tumores compreendendo derivados de acriloil distamicina substituìda e radioterapia | |
MX2023003034A (es) | Metodos, terapias y usos para tratar el cancer. | |
MXPA05002477A (es) | Asialo-interferones y el tratamiento de cancer de higado. | |
DK1133297T3 (da) | Ny terapeutisk anvendelse af 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin | |
WO2003007800A8 (en) | Methods for diagnosing and treating diseases and conditions of the digestive system and cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 6A., 7A. E 8A. ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010. |
|
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 45/06 (2006.01), A61P 35/00 (2006.01) |